WO1993023066A1 - Promoteur de croissance de plaquettes - Google Patents

Promoteur de croissance de plaquettes Download PDF

Info

Publication number
WO1993023066A1
WO1993023066A1 PCT/JP1993/000487 JP9300487W WO9323066A1 WO 1993023066 A1 WO1993023066 A1 WO 1993023066A1 JP 9300487 W JP9300487 W JP 9300487W WO 9323066 A1 WO9323066 A1 WO 9323066A1
Authority
WO
WIPO (PCT)
Prior art keywords
platelet count
group
day
administration
blood
Prior art date
Application number
PCT/JP1993/000487
Other languages
English (en)
Japanese (ja)
Inventor
Masahiro Maeda
Susumu Sato
Kazuyuki Otsuka
Shingo Suzuki
Mineo Niwa
Fusako Nishigaki
Kyoichi Shimomura
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of WO1993023066A1 publication Critical patent/WO1993023066A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides

Definitions

  • the present invention relates to a platelet number enhancer (platelet number increasing agent) containing FK 565 represented by the following formula or a pharmaceutically acceptable salt thereof as an active ingredient, and is used in the field of medicine.
  • FK565 has an immunopotentiating effect and is known to be useful as an anticancer agent, an anti-AIDS agent, an antiviral agent, etc. (Japanese Patent Application Laid-Open Nos. 56-45449, 60-104019) And JP-A-64-38030).
  • the invention is based on the formula
  • F ⁇ 565 or a pharmaceutically acceptable salt thereof is useful as a platelet count reduction inhibitor, a decreased platelet count increase agent, a prophylactic or therapeutic agent for thrombocytopenia, a prophylactic or therapeutic agent for purpura, etc. is there.
  • F ⁇ 565 or a pharmaceutically acceptable salt thereof is, for example, Since it antagonizes side effects such as thrombocytopenia due to administration of anti-cancer drugs without impairing the efficacy of anti-cancer drugs such as ittomycin C and cis-bratin, it is also useful as an anti-cancer drug side effect reducer is there.
  • Pharmaceutically acceptable salts of FK565 include, for example, organic or inorganic salts such as sodium salt, potassium salt, calcium salt, ammonium salt, ethanolamine salt, triethylamine salt, dicyclohexylamine salt, and severe acids.
  • Organic or inorganic acids such as salt, trifluorophosphate, lactate, maleate, fumarate, tartrate, citrate, methanesulfonate, hydrochloride, sulfate, ganate, phosphate, etc.
  • the FK565 of the present invention can be used in the form of a solid, semisolid or liquid preparation containing a mixture with an organic or inorganic carrier or excipient suitable for oral or parenteral administration.
  • the FK565 of the present invention is used in, for example, tablet pellets, capsules, suppositories, solutions, emulsions, suspensions, and usually mixed with non-toxic and pharmaceutically acceptable carriers to form appropriate dosage forms.
  • the carriers used here are water, glucose, lactose, gum arabic, gelatin, mannitol, starch paste, magnesium sulfate, talc, methylcellulose, polyethylene glycol, corn starch, keratin, colloidal silica, and potato starch.
  • FK565 When FK565 is applied to humans or animals, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection or oral administration.
  • the dose of FK565 of the present invention varies depending on conditions such as the age of each individual patient to be treated and the degree of the disease, but generally, the daily dose of the active ingredient for humans or animals is high. 0.01-1 Omg / kg is administered for prophylaxis or treatment. The platelet count increasing activity of FK565 will be described below.
  • a single intravenous dose of FK565 (0.1 mg / kg or 0.1 mg / kg) is given to three normal cynomolgus monkeys, blood is collected daily, and the platelet count is measured by SysmexE—4000 (automatic blood cells). The number was automatically measured using a counting device (Toa Medical Electronics Co., Ltd.). As a control, blood was collected from the same individual the day before administration. Separately, a saline was administered to the control group.
  • the platelet count in each group was calculated by setting the platelet count on the day before the administration as 100% for the platelet count in each dose.
  • Table 1 shows the test results.
  • FK565 (0.01 mg / kg. O.lmgZkg or l.OmgZkg) was administered to normal mice (five ddY female mice (7 weeks old) purchased from Nippon S.L.C.) in a single intravenous dose of 25 mg / day. Blood samples were collected and the platelet count was automatically measured using Sysmex E-4000. Separately, a saline was administered to the control group.
  • the platelet count in each dose was calculated with the platelet count in the control group taken as 100%.
  • Table 2 shows the test results. Test results
  • mice (ddY female mice (7 weeks old) purchased from Japan SLC, Inc.) FK565 (0.01 mg / kg. O.lmgZkg or l.Omg / kg) once a day for 3 days, and blood is collected daily, and the platelet count is measured using Sysmex E-4000. And automatic measurement. Separately, saline was administered to the control group.
  • the platelet count in each dose was calculated with the platelet count in the control group taken as 100%.
  • FK565 O.lmgZkg or l.OmgZkg
  • normal mice five ddY female mice (7-week-old) purchased from Nippon S.L.C.
  • the platelet count was automatically measured using Sysmex E-4000.
  • mice normal mice (ddY female mice (7 weeks old) purchased from S.L.C.) FK565 (0.01 mg / kg, O.lmg / Zkg or l.Omg / kg) was administered once intravenously or orally to 5 of them, and blood was collected daily and the platelet count was measured using Sysmex E-4000. Was measured automatically. A saline was administered to the control group.
  • the change in platelet count at each dose is calculated as u.
  • MMC manufactured by Kyowa Hakko Co., Ltd.
  • 5.6 mg Zkg was intravenously administered to ddY female 'mice (7 weeks old) (5 animals per group) (this administration day is hereafter referred to as dayO.
  • the day is called day2.
  • FK565 0.1 mg / kg was intravenously administered once a day from dayO to 2 for 3 days, blood was collected on day9, and the platelet count was measured automatically using Sysmex E-4000.
  • a group to which MMC was administered but not to FK565 was used as a control.
  • the change in platelet count in each group was calculated with the platelet count in the group (saline-administered group) not receiving MMC as 100%.
  • MMC manufactured by Kyowa Hakko Co., Ltd.
  • MMC manufactured by Kyowa Hakko Co., Ltd.
  • FK565 O.lmgZkg once daily
  • the dose was intravenously administered for four days from day O to 3, and blood was collected on day 8 and day 10 and the platelet count was automatically measured using Sysmex E-4000.
  • a group to which MMC was administered but not to FK565 was used as a control.
  • the change in platelet count in each group was calculated, with the platelet count in the group not receiving MMC (saline-administered group) as 100%.
  • the platelet count gradually decreased and reached a nadir at day 10 (down to 32.6% of the saline-administered control group), and then recovered slowly.
  • the decrease in platelet count due to MMC administration was significantly suppressed at daylO.
  • Blood was collected from the brachial vein of the monkey using a 2.5 ml syringe (pre-filled with 15% EDTA4Na (pH 8.0) 20 / z1 as an anticoagulant). It was stored under ice cooling until the platelet count was measured.
  • FK565 is useful for the treatment and prevention of thrombocytopenia caused by anticancer drugs and the like.
  • Starch 50mg The above components are formulated into tablets by a conventional method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Promoteur de croissance de plaquettes contenant du FK566, substance représentée par la formule (I), ou sel de cette substance, pharmaceutiquement acceptable en tant qu'ingrédient actif.
PCT/JP1993/000487 1992-05-08 1993-04-15 Promoteur de croissance de plaquettes WO1993023066A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14317492 1992-05-08
JP4/143174 1992-05-08

Publications (1)

Publication Number Publication Date
WO1993023066A1 true WO1993023066A1 (fr) 1993-11-25

Family

ID=15332638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1993/000487 WO1993023066A1 (fr) 1992-05-08 1993-04-15 Promoteur de croissance de plaquettes

Country Status (2)

Country Link
AU (1) AU3905393A (fr)
WO (1) WO1993023066A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01131121A (ja) * 1987-08-24 1989-05-24 Pitman Moore Inc 寄生体を制御する方法
EP0488041A2 (fr) * 1990-11-26 1992-06-03 Fujisawa Pharmaceutical Co., Ltd. Une composition pharmaceutique contre l'infection de cytomégalovirus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01131121A (ja) * 1987-08-24 1989-05-24 Pitman Moore Inc 寄生体を制御する方法
EP0488041A2 (fr) * 1990-11-26 1992-06-03 Fujisawa Pharmaceutical Co., Ltd. Une composition pharmaceutique contre l'infection de cytomégalovirus

Also Published As

Publication number Publication date
AU3905393A (en) 1993-12-13

Similar Documents

Publication Publication Date Title
JP6244497B1 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
KR100638684B1 (ko) 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
JP2012102118A (ja) β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法
CZ355897A3 (cs) Způsob léčení mánie a bipolárních poruch
CA1228818A (fr) Traitement de l'epilepsie et composes pharmaceutiques utilises a cette fin
RU2341261C2 (ru) Композиции, содержащие эпотилоны, и их применение для лечения карциноидного синдрома
EP1084704B1 (fr) Traitements de l'ataxie spinocerebelleuse et compositions utiles pour traiter l'ataxie spinocerebelleuse
JPH1017478A (ja) 潰瘍性大腸炎の予防又は治療剤
WO1993023066A1 (fr) Promoteur de croissance de plaquettes
EP0290817B1 (fr) Utilisation d'oxétanocine pour inhiber HIV
AU2017305661B2 (en) New use of N,N-bis-2-mercaptoethyl isophthalamide
JPH05504550A (ja) 免疫抑制剤として有用なピリミジン生合成インヒビター
JP5376786B2 (ja) 神経細胞賦活組成物
US3852454A (en) Treatment of rheumatoid arthritis
US4517309A (en) Method for the treatment of calcifying pancreatitis
JP7257091B2 (ja) 認知症の治療及び予防薬
JPWO2004096230A1 (ja) 関節リウマチ治療剤
CA2076005A1 (fr) Utilisation d'antogonistes du recepteur de la thromboxane-a2 pour la prevention de la degenerescence du tissu penien
JPH0539226A (ja) サイトメガロウイルス感染症用薬剤
JP3006695B2 (ja) 腫瘍壊死因子産生促進剤
JPH05170653A (ja) 糖尿病治療剤
CN100560075C (zh) 调节脂类代谢的药物
JPH10505323A (ja) ２−ハロ−２’−デオキシアデノシンによる炎症性腸疾患の治療
WO2018034351A1 (fr) Agent préventif ou thérapeutique pour l'hypertension pulmonaire comprenant un composant de médicament brut
WO2007018281A1 (fr) INHIBITEUR DE L'ACTIVATION DE L’Akt

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA